OGEN · Oragenics Inc
$0.51
+0.01 (+2.31%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.25M
Shares
4.51M
OGEN metrics
55 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.50
Market cap
$2.25M
Price action
19 metricsPrice change (1W)
-6.3%
Price change (30D)
-7.7%
Price change (3M)
-16.9%
Price change (6M)
-44.0%
Price change (YTD)
-36.1%
Price change (1Y)
-53.4%
Trailing year
Price change (5Y)
—
52-week high
$1.42
52-week low
$0.49
Change from 52-week high
-64.9%
Change from 52-week low
+1.7%
Annualized volatility
69.1%
Beta
1.5
RSI (14D)
37.2
Price vs SMA 50
-8.0%
Price vs SMA 200
-27.9%
Avg volume (3M)
33,669
Relative volume
0.7
Average dollar volume
$18,737
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
4.51M
Valuation
12 metricsP / E (TTM)
0.4
Trailing earnings · reciprocal yield 222.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
59.7×
reciprocal yield 1.7%
P / book
0.6
reciprocal yield 163.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-448.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-55,519.9%
Trailing 12 months
Net margin
-54,858.1%
Gross profit (TTM)
$0
Operating profit (TTM)
−$10.47M
Net income (TTM)
−$10.08M
Trailing 12 months
Diluted EPS (TTM)
$1.11
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-71.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$37,653
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+505.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-274.7%
Return on assets
-183.6%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
−$20.88M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-561.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.86M
Total assets
$5.49M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$10.21M
Capital expenditures (TTM)
$127,519
R&D (TTM)
$3.42M
SG&A (TTM)
$3.91M
Stock compensation (TTM)
$652,848
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
18
13F filer change QoQ
-4
Institutional ownership
1.5%
Short interest
3 metricsShort interest
17.5%
Latest settlement · 39.1 days to cover
Days to cover
39.1d
Short-squeeze score
79 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1174940
CUSIP
684023609
13F (30d)
12 filings
12 filers
Visit website
Investor relations